Ab Initio Pharma receives APVMA GMP licence to manufacture veterinary products
Ab Initio is pleased to announce that it has received its GMP Licence for the manufacture and testing of veterinary products from the Australian Pesticides and Veterinary Medicines Authority (APVMA). The APVMA licence will allow Ab Initio to manufacture and test numerous veterinary medicines under GMP, including liquids, granules, capsules, creams, gels and inhalation products.
Dr Will Glover, COO and Head of Quality said “Our APVMA licence will allow Ab Initio to provide the full suite of R&D and GMP services to for animal medicines as we already do for human products. Our R&D team can take an existing or new drug and formulate in such a way that it is optimised for a particular animal. This can now be seamless transferred to our GMP facility and manufactured to the same standards as would be required for human medicines.”
“Our APVMA licence will allow Ab Initio to provide the full suite of R&D and GMP services for Animal medicines as we already do for Human products. ”
To learn more about Ab Initio’s R&D and GMP services, and how we can help take a molecule from bench to patient (or pet) visit www.ab-initio-pharma.com
